Atty. Dkt. No. 077319-0382

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: David W. LEUNG et al.

Title: METHOD OF SCREENING COMPOUNDS THAT INHIBIT

LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE

Appl. No.: Unassigned

Filing Date: 09/23/2003

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop PATENT APPLICATION Commissioner for Patents PO Box 1450

Alexandria, Virginia 22313-1450

Sir:

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to Pre-OG Notice from Office of Patent Legal Administration dated July 25, 2003, Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/970,989, filed 10/05/2001. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

Atty. Dkt. No. 077319-0382

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP 8609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 23 September 2003 By Stephen A. Ben

Customer Number: 22428
Telephone: (202) 672-5404

Facsimile: (202) 672-5399

Stephen A. Bent Attorney for Applicants Registration No. 29,768

002 1078932 1

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.

	Substitute for form	1449B/	PTO		Complete if Known		
	INFORMATION DIS	SCLO	SURE	Application Number	Unassigned		
	STATEMENT BY A	APPLI	CANT	Filing Date	09/23/2003		
	Date Submitted: Septe	mhar	23 2003	First Named Inventor	David W. LEUNG		
	·			Group Art Unit	Unassigned		
	(use as many sheets	as ne	cessary)	Examiner Name	Unassigned		
Sheet	1	of	2	Attorney Docket Number	077319-0382		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines,	
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
	A1	5,888,793	A	HILLMAN et al.	03-30-1999		
	A2	6,001,620	Α	HILLMAN et al.	12-14-1999		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ,
	А3	BROWN et al., "Isolation and characterisation of a maize cDNA that complements a 1-acyl sn-gloerol-3- phosphate acyltransferase mutant of <i>Escherichia coli</i> and encodes a protein which has similarities to other acyltransferases, "Plant Molecular Biology, October 1994, pp. 211-223, Vol. 26, No. 1, Kluwer Academic Publishers, Belgium	
	A4	BROWN et al., "Identification of cDNA that encodes a 1-acyl-sr-glycerol-3-phosphate acyltransferase from Limnanthes douglasii," <u>Plant Molecular Biology</u> , October 1995, pp. 267-278, Vol. 29, No. 2, Kluwer Academic Publishers, Belguim	
	A5	COLEMAN et al., "Characterization of the Escherichia coli gene for 1-acyl-sn-glycerol-3-phosphate acyltransferase (plsC)," Mol. Gen. Genet., 1992, pp. 295-303, Vol. 232, No. 2, Springer-Verlag	
	A6	HANKE et al., "A plant acyltransferase involved in triacylglycerol biosynthesis complements an <i>Escherichia</i> coli sn-1-acylglycerol-3-phosphate acyltransferase mutant," <u>Eur. J. Biochem.</u> , September 1995, pp. 806-810, Vol. 232, No. 3, Springer International	
	A7	KNUTZON et al., "Cloring of a Cocunut Endosperm cDNA Encoding a 1-Acyl-sr-Glycerol-3-Phosphate Acyltransferase That Accepts Medium-Chain-Length Substrates," <u>Plant Physiol.</u> , November 1995, pp. 999-1006, Vol. 109, No. 3	
	A8	LASSNER et al., "Lysophosphatidic Acid Acyltransferase from Meadowfoam Mediates Insertion of Erucic Acid at the sn-2 Position of Triacylglycerol in Transgenic Rapeseed Oil," <u>Plant Physiol.</u> , December 1995, pp. 1389-1394, Vol. 109, No. 4	
	A9	NAGIEC et al., "A Suppressor Gene That Enables Saccharomyces cerevisiae to Grow without Making Sphingolipids Encodes a Protein That Resembles an Escherichia colf Fatty Acyltransferase," The Journal of Biological Chemistry, October 15, 1993, pp. 22156-22163, Vol. 268, No. 29, The American Society for Biochemistry and Molecular Biology, Inc., USA	

Examiner		Date						
Signature		Considered						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Surfain from Statement. This form is estimated to take 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on mount of time you are required to complete this form should be sent to the Chef Information Officer, U.S. Patient and Trademark Office, Washington, D.C. 2021. 20.407 Selfor PECS OF COMPLETED FORMS TO THIS ADDRESS. SENT DT O. Sakstaint Commissioner for Patients, Washington, D.C. 2021.

^{*}Unique classion designation number. *See situational training of the Comments. *Plate Office that issued the document, by the two-letter code (WIPO Standard 87.3). *Por Augustee patient inducement, the Indication of the year of the resign of the Emperor must precede the send number of the patient document. **Nind of document by the appropriate symbols as indicated on the document under WIPO Standard 51.3 14 possible. **Applicant is to place a check mark haref

PTO/SB/08 (08-00)

Approved for use through 10/31/2002, OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.							
$\overline{}$	Substitute for form	1449B.	/PTO		C mplete if Known		
ł	INFORMATION DI	SCLO	SURE	Applicati n Number	Unassigned		
ł .	STATEMENT BY A	PPLI	CANT	Filing Date	09/23/2003		
1	Date Submitted: Septe		22 2002	First Named Inventor	David W. LEUNG		
1	Date Submitted: Septe	moer	23, 2003	Group Art Unit	Unassigned		
1	(use as many sheets	as ne	cessary)	Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	077319-0382		

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*			T ⁶				
	A10	WEST et al., "Cloning and Expression of Two Human Lysophosphatidic Acid Acyltransferase cDNAs That Enhance Cytokine-Induced Signaling Responses in Cells," <u>DNA and Cell Biology</u> , June 1997, Vol. 16, No. 6, Mary Ann Liebert, Inc., USA					
	A11	SWARTLEY et al., "Membrane glycerophospholipid biosynthesis in <i>Neisseria meningitidis</i> and <i>Neisseria gonorrhoeae</i> : identification, characterization, and mutagenesis of a lysophosphatidic acid acytransferase," Molecular Microbiology , November 1995, pp. 401-412, Vol. 18, No. 3, Blackwell Science Ltd.					
			-				
			T				
			T				

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{*}Unique diation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the healette code (WPO Standard ST3.)* *Cert Spansese patent document, be indication of the year of the reign of the Emperor must preced the set all number bearted counter, *Vand of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English Inquages Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 2023.1. ON OTS PSEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TC. Assistant Commissioner for Patents, Washington, D.C. 2023.1.